Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/HDAC9_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/HDAC9_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/HDAC9_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/HDAC9_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/HDAC9_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/HDAC9_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/HDAC9_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001063223 | Oral cavity | NEOLP | regulation of epithelial cell migration | 56/2005 | 292/18723 | 1.07e-05 | 1.98e-04 | 56 |
GO:001470621 | Oral cavity | NEOLP | striated muscle tissue development | 69/2005 | 384/18723 | 1.11e-05 | 2.06e-04 | 69 |
GO:003009821 | Oral cavity | NEOLP | lymphocyte differentiation | 66/2005 | 374/18723 | 3.08e-05 | 4.67e-04 | 66 |
GO:003286832 | Oral cavity | NEOLP | response to insulin | 50/2005 | 264/18723 | 4.35e-05 | 6.13e-04 | 50 |
GO:001063424 | Oral cavity | NEOLP | positive regulation of epithelial cell migration | 37/2005 | 176/18723 | 4.37e-05 | 6.14e-04 | 37 |
GO:001820531 | Oral cavity | NEOLP | peptidyl-lysine modification | 64/2005 | 376/18723 | 1.21e-04 | 1.43e-03 | 64 |
GO:005114615 | Oral cavity | NEOLP | striated muscle cell differentiation | 51/2005 | 283/18723 | 1.37e-04 | 1.60e-03 | 51 |
GO:000751714 | Oral cavity | NEOLP | muscle organ development | 56/2005 | 327/18723 | 2.65e-04 | 2.70e-03 | 56 |
GO:001059514 | Oral cavity | NEOLP | positive regulation of endothelial cell migration | 28/2005 | 133/18723 | 3.44e-04 | 3.33e-03 | 28 |
GO:006053813 | Oral cavity | NEOLP | skeletal muscle organ development | 32/2005 | 166/18723 | 7.05e-04 | 5.81e-03 | 32 |
GO:004353613 | Oral cavity | NEOLP | positive regulation of blood vessel endothelial cell migration | 18/2005 | 76/18723 | 9.09e-04 | 7.10e-03 | 18 |
GO:001059414 | Oral cavity | NEOLP | regulation of endothelial cell migration | 40/2005 | 232/18723 | 1.64e-03 | 1.14e-02 | 40 |
GO:004353413 | Oral cavity | NEOLP | blood vessel endothelial cell migration | 32/2005 | 176/18723 | 1.93e-03 | 1.30e-02 | 32 |
GO:000751912 | Oral cavity | NEOLP | skeletal muscle tissue development | 29/2005 | 155/18723 | 1.97e-03 | 1.32e-02 | 29 |
GO:000647631 | Oral cavity | NEOLP | protein deacetylation | 21/2005 | 101/18723 | 2.11e-03 | 1.39e-02 | 21 |
GO:005500111 | Oral cavity | NEOLP | muscle cell development | 32/2005 | 184/18723 | 3.95e-03 | 2.26e-02 | 32 |
GO:0002040 | Oral cavity | NEOLP | sprouting angiogenesis | 32/2005 | 185/18723 | 4.29e-03 | 2.42e-02 | 32 |
GO:000197512 | Oral cavity | NEOLP | response to amphetamine | 9/2005 | 33/18723 | 6.45e-03 | 3.32e-02 | 9 |
GO:003560131 | Oral cavity | NEOLP | protein deacylation | 21/2005 | 112/18723 | 7.48e-03 | 3.74e-02 | 21 |
GO:0030183 | Oral cavity | NEOLP | B cell differentiation | 25/2005 | 141/18723 | 7.85e-03 | 3.90e-02 | 25 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HDAC9 | SNV | Missense_Mutation | | c.3178N>A | p.Gly1060Ser | p.G1060S | Q9UKV0 | protein_coding | tolerated(0.21) | benign(0.168) | TCGA-A2-A0D2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
HDAC9 | SNV | Missense_Mutation | | c.2057N>T | p.Arg686Leu | p.R686L | Q9UKV0 | protein_coding | deleterious(0.01) | probably_damaging(0.992) | TCGA-A2-A0SV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate therapy | zometa | PD |
HDAC9 | SNV | Missense_Mutation | | c.1846N>T | p.Pro616Ser | p.P616S | Q9UKV0 | protein_coding | deleterious(0.01) | possibly_damaging(0.696) | TCGA-AR-A251-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
HDAC9 | SNV | Missense_Mutation | | c.407G>C | p.Gly136Ala | p.G136A | Q9UKV0 | protein_coding | deleterious(0.04) | benign(0.164) | TCGA-BH-A0B7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
HDAC9 | SNV | Missense_Mutation | novel | c.2986N>T | p.Ala996Ser | p.A996S | Q9UKV0 | protein_coding | deleterious(0.01) | probably_damaging(0.988) | TCGA-E2-A15M-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
HDAC9 | SNV | Missense_Mutation | | c.2093C>T | p.Ser698Phe | p.S698F | Q9UKV0 | protein_coding | deleterious(0.01) | possibly_damaging(0.852) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
HDAC9 | SNV | Missense_Mutation | | c.839N>T | p.Ser280Leu | p.S280L | Q9UKV0 | protein_coding | tolerated(0.08) | probably_damaging(0.994) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
HDAC9 | SNV | Missense_Mutation | | c.1096N>T | p.Pro366Ser | p.P366S | Q9UKV0 | protein_coding | tolerated(0.33) | benign(0) | TCGA-FU-A23L-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HDAC9 | SNV | Missense_Mutation | | c.702A>C | p.Lys234Asn | p.K234N | Q9UKV0 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HDAC9 | SNV | Missense_Mutation | novel | c.2773C>T | p.Pro925Ser | p.P925S | Q9UKV0 | protein_coding | tolerated(0.07) | possibly_damaging(0.692) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
9734 | HDAC9 | TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | inhibitor | SB939 | | |
9734 | HDAC9 | TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | inhibitor | PCI-24781 | ABEXINOSTAT | |
9734 | HDAC9 | TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | inhibitor | 310264675 | CUDC-101 | |
9734 | HDAC9 | TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | MOCETINOSTAT | MOCETINOSTAT | 23829483,26287310 |
9734 | HDAC9 | TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | BUTYRYLHYDROXAMIC ACID | BUTYRYLHYDROXAMIC ACID | 21874153 |
9734 | HDAC9 | TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | inhibitor | ROMIDEPSIN | ROMIDEPSIN | |
9734 | HDAC9 | TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | PMID29671355-Compound-25 | | |
9734 | HDAC9 | TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | SUBEROHYDROXAMIC ACID | SUBEROHYDROXAMIC ACID | 16921367 |
9734 | HDAC9 | TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | inhibitor | CUDC-101 | CUDC-101 | |
9734 | HDAC9 | TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | VORINOSTAT | VORINOSTAT | |